Objectives: SSc is a devastating disease that results in fibrosis of the skin and other organs. Fibroblasts are a key driver of the fibrotic process through deposition of extracellular matrix. The mechanisms by which fibroblasts are induced to become pro-fibrotic remain unclear. Thus, we examined the ability of SSc keratinocytes to promote fibroblast activation and the source of this effect. Methods: Keratinocytes were isolated from skin biopsies of 9 lcSSc, 10 dcSSc and 13 control patients. Conditioned media was saved from the cultures. Normal fresh primary fibroblasts were exposed to healthy control and SSc keratinocyte conditioned media in the presence or absence of neutralizing antibodies for TGF-β. Gene expression was assessed by microarrays and real-time PCR. Immunocytochemistry was performed for α-smooth muscle actin (α-SMA), collagen type 1 (COL1A1) and CCL5 expression. Results: SSc keratinocyte conditioned media promoted fibroblast activation, characterized by increased α-SMA and COL1A1 mRNA and protein expression. This effect was independent of TGF-β. Microarray analysis identified upregulation of nuclear factor κB (NF-κB) and downregulation of peroxisome proliferator-activated receptor γ (PPAR-γ) pathways in both SSc subtypes. Scleroderma keratinocytes exhibited increased expression of NF-κB-regulated cytokines and chemokines and lesional skin staining confirmed upregulation of CCL5 in basal keratinocytes. Conclusion: Scleroderma keratinocytes promote the activation of fibroblasts in a TGF-β-independent manner and demonstrate an imbalance in NF-κB1 and PPAR-γ expression leading to increased cytokine and CCL5 production. Further study of keratinocyte mediators of fibrosis, including CCL5, may provide novel targets for skin fibrosis therapy.
Objectives: SSc is a devastating disease that results in fibrosis of the skin and other organs. Fibroblasts are a key driver of the fibrotic process through deposition of extracellular matrix. The mechanisms by which fibroblasts are induced to become pro-fibrotic remain unclear. Thus, we examined the ability of SSc keratinocytes to promote fibroblast activation and the source of this effect. Methods: Keratinocytes were isolated from skin biopsies of 9 lcSSc, 10 dcSSc and 13 control patients. Conditioned media was saved from the cultures. Normal fresh primary fibroblasts were exposed to healthy control and SSc keratinocyte conditioned media in the presence or absence of neutralizing antibodies for TGF-β. Gene expression was assessed by microarrays and real-time PCR. Immunocytochemistry was performed for α-smooth muscle actin (α-SMA), collagen type 1 (COL1A1) and CCL5 expression. Results: SSc keratinocyte conditioned media promoted fibroblast activation, characterized by increased α-SMA and COL1A1 mRNA and protein expression. This effect was independent of TGF-β. Microarray analysis identified upregulation of nuclear factor κB (NF-κB) and downregulation of peroxisome proliferator-activated receptor γ (PPAR-γ) pathways in both SSc subtypes. Scleroderma keratinocytes exhibited increased expression of NF-κB-regulated cytokines and chemokines and lesional skin staining confirmed upregulation of CCL5 in basal keratinocytes. Conclusion: Scleroderma keratinocytes promote the activation of fibroblasts in a TGF-β-independent manner and demonstrate an imbalance in NF-κB1 and PPAR-γ expression leading to increased cytokine and CCL5 production. Further study of keratinocyte mediators of fibrosis, including CCL5, may provide novel targets for skin fibrosis therapy.
Authors: O Distler; B Rinkes; U Hohenleutner; J Schölmerich; M Landthaler; B Lang; S Gay; U Müller-Ladner Journal: Rheumatol Int Date: 1999 Impact factor: 2.631
Authors: Lisa M Rice; Cristina M Padilla; Sarah R McLaughlin; Allison Mathes; Jessica Ziemek; Salma Goummih; Sashidhar Nakerakanti; Michael York; Giuseppina Farina; Michael L Whitfield; Robert F Spiera; Romy B Christmann; Jessica K Gordon; Janice Weinberg; Robert W Simms; Robert Lafyatis Journal: J Clin Invest Date: 2015-06-22 Impact factor: 14.808
Authors: A Leask; D J Abraham; D R Finlay; A Holmes; D Pennington; X Shi-Wen; Y Chen; K Venstrom; X Dou; M Ponticos; C Black; C Bernabeu; J K Jackman; P R Findell; M K Connolly Journal: Arthritis Rheum Date: 2002-07
Authors: Britta Maurer; Alfiya Distler; Yossra A Suliman; Renate E Gay; Beat A Michel; Steffen Gay; Jörg H W Distler; Oliver Distler Journal: Ann Rheum Dis Date: 2013-08-05 Impact factor: 19.103
Authors: Michael L Whitfield; Deborah R Finlay; John Isaac Murray; Olga G Troyanskaya; Jen-Tsan Chi; Alexander Pergamenschikov; Timothy H McCalmont; Patrick O Brown; David Botstein; M Kari Connolly Journal: Proc Natl Acad Sci U S A Date: 2003-10-06 Impact factor: 11.205
Authors: Djúlio C Zanin-Silva; Maynara Santana-Gonçalves; Marianna Y Kawashima-Vasconcelos; João R Lima-Júnior; Juliana B E Dias; Daniela A Moraes; Dimas T Covas; Kelen C R Malmegrim; Leandra Ramalho; Maria Carolina Oliveira Journal: Arthritis Res Ther Date: 2022-04-29 Impact factor: 5.606
Authors: Chenfu Shi; Helen Ray-Jones; James Ding; Kate Duffus; Yao Fu; Vasanthi Priyadarshini Gaddi; Oliver Gough; Jenny Hankinson; Paul Martin; Amanda McGovern; Annie Yarwood; Patrick Gaffney; Steve Eyre; Magnus Rattray; Richard B Warren; Gisela Orozco Journal: J Invest Dermatol Date: 2021-02-17 Impact factor: 8.551